Corrigendum to “Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: effects on weight loss and safety in adults with overweight or obesity” [Mol Metab 78 (2023) 101801]
Martin Haljeta Friedrichsen,
Lars Endahl,
Frederik Flindt Kreiner,
Ronald Goldwater,
Martin Kankam,
Søren Toubro,
Sune Boris Nygård
Affiliations
Martin Haljeta Friedrichsen
Novo Nordisk A/S, Søborg, Denmark; Corresponding author. Dr Martin Haljeta Friedrichsen, Novo Nordisk A/S, Vandtårnsvej 108, Suborn, DK-2860, Denmark.
Lars Endahl
Novo Nordisk A/S, Søborg, Denmark
Frederik Flindt Kreiner
Novo Nordisk A/S, Søborg, Denmark
Ronald Goldwater
Parexel International, Baltimore, MD, USA
Martin Kankam
Altasciences Clinical Kansas, Overland Park, KS, USA
